or those with cancer, because it is widely accepted that vaccination of such persons provides cost savings. The aim was to calculate the costs and benefits of routine varicella vaccination, if the varicella vaccine was administered jointly with a measles-mumps-rubella (MMR) injection, from a narrow medical care payer point of view (only direct costs included) and from a broader societal perspective (including also the indirect costs of parents' work loss). All future costs and benefits occurring within 70 years were discounted to their present values using a 5% discount rate (1995 German price level).
Vaccination Strategies
Three routine intervention strategies against varicella were compared with nonintervention: (1) vaccination of all healthy children between the ages of 12 and 18 months (hereafter called 15 months), which we termed the "children" strategy; (2) vaccination of all healthy 12-year-olds with a negative history of varicella infection (no serologic testing), the "adolescent" strategy; and (3) vaccination of all healthy children between the ages of 12 and 18 months and for 11 years the vaccination of all healthy I2-year-olds with a negative history of varicella infection (no serologic testing), the "children including catch-up" strategy.
The third option was an attempt to prevent older children from growing up susceptible to varicella because of a reduction in varicella transmission resulting from the widespread immunization of infants. Each year, those who turned 12-years-old would be vaccinated until eventually in 11 years, all who are now between the ages of 15 months and 12 years would have "caught up" with the immunization program. The expected costs and benefits for each strategy were calculated and compared with that of no prevention, and the benefit-to-cost ratios (BCRs) and cost-effectiveness ratios (CERs) of the three strategies were compared.
Varicella: Incidence, Hospitalizations, and Deaths
Since there has not been any influence of vaccination on the natural development of varicella, data are available on prevalence, complications, and hospitalizations in a nonimmunized population. However, in the absence of published German data, we had to adapt US prevalence data for the German population [7] .
By assuming that the incidence of varicella is constant over short intervals, the annual attack rate can be derived from prevalence data over these periods. For instance, if we know that of 100 susceptible persons at the beginning of their first year of life, 45 will remain susceptible at the end of year 5 (table 1), then the annual attack rate (r) in susceptibles can be calculated as 45 = 100(1 -r)5, where r = 1 -(45/100)1/5 = 0.147602, or, in general, as r = 1 -(Se/Sh)l/n, when Sb = percentage of susceptibles at the beginning of the interval, S; = percentage of susceptibles at the end of the interval, n = number of years in the interval, and r = annual attack rate in susceptibles. The annual attack rates for the other time intervals used in the model were calculated similarly and are shown in table I. These age-specific attack rates do not differ markedly from those presented by Halloran et al. [8] .
Treatment costs differ depending on the severity of disease. In this study, a distinction was made between uncomplicated varicella and varicella giving rise to complications, such as bacterial superinfection, encephalitis, and pneumonia. The age-specific annual rates of complications, hospitalizations, and deaths due to varicella disease that were used as input for the model were obtained from previously published data [3, 9] .
Vaccine Effectiveness
The vaccination characteristics used in the model were simple: (1) Only one dose was needed for healthy children; (2) the vaccine's efficacy (not to be confused with the seroconversion rate) was estimated at 90% [10] ; (3) protection against serious disease was assumed to be life-long in 85% of the protected vaccinees, since in 15% of successfully vaccinated persons, immunity is assumed to have waned by the end of life [11] ; (4) on the basis of coverage of measles vaccination in Germany, the coverage rate was set at 70% [12] ; and (5) as suggested by prior studies, adverse events due to vaccination were assumed to be nonexistent [13, 14] . By making these assumptions, we neglected some long-term effects in vaccinees, such as relative infectiousness and boosting through natural infection. Relative infectiousness takes into account the lower probability of transmission of infection by a previously vaccinated person who becomes infected with chickenpox to an unvaccinated susceptible person; the boosting effect is related to vaccinated persons becoming completely resistant after exposure to wild type varicella [6] . These parameters were not included primarily because there are no accurate estimates for them.
Economic Data
Direct costs. Direct costs are treatment and intervention costs for varicella and its complications. We first considered costs incurred by visits to physicians. A survey of 216 German parents showed that in 10% of varicella cases no physician is consulted, whereas one visit is made in 30% of cases, two visits in 40%, and three to five visits in 20% [15] . A pediatrician is consulted in person or by telephone in 90% of these visits, and a general practitioner is consulted in 10%. The rounded weighted average cost of a consultation with a pediatrician and with a general practitioner was calculated at DM 40 and 20, respectively. The weighted average considered private and panel patients (private patients can change physicians; panel patients always see the same doctor), home and office visits, phone and personal consultations, and weekend and weekday consultations.
For uncomplicated varicella and for varicella with bacterial superinfection (by far the largest group of varicella cases), medication includes antibiotics (mean, DM 4/patient), antipruritics (mean, DM 10/patient), and acyclovir (per 800 mg, DM 427.9; mean, DM 12.8 and 427.9/patient < 14-and > 14-years-old, respectively). To treat chronic lung and skin disorders associated with varicella, acyclovir is thought to be prescribed for 5% ofchildren < 14-yearsold; however, because of current treatment recommendations, we estimate that acyclovir is prescribed for all varicella patients ;:=: 14-years-old [16] . Therefore, acyclovir (which accounts for~83% of medical costs associated with varicella) is the most important cost item for ambulatory patients > 14-years-old. For younger ambulatory patients, the cost of acyclovir represents only 13% of all medical treatment costs.
Hospitalization costs, determined after consultation between German and Belgian experts, were defined as hospitalization 5-7 days in a general ward at DM 500/day and 0-7 days in intensive care at DM 1500/day, and follow-up costs (including long-term care for sequelae in 3% of encephalitis cases [4] ) were estimated as DM 50,000/year [17] ). These were added to derive total expected treatment costs for each typical varicella-related illness. The results, in unit costs per ambulatory treated uncomplicated varicella cases, were DM 99 and 514 for persons < 14-and ;:=: 14-yearsold, respectively. For hospitalized uncomplicated cases (including bacterial skin infection), the cost was DM 3015. Treatment costs for pneumonia and encephalitis due to varicella were DM 5663 and 35,543, respectively.
Relevant intervention costs are the marginal or incremental costs of adding varicella vaccination to existing immunization programs. The cost of a dose of varicella vaccine given jointly with the MMR vaccine was estimated as DM 75. Although the marginal administration costs can be argued to be none because the MMR vaccine is given anyway, we chose to attribute one-half of the overall administration costs of the MMR plus varicella vaccines (DM 10) to the specific vaccination against varicella. The overall administration costs of MMR plus varicella vaccine are estimated as ::o:::;DM 10, because routine vaccination would be put into practice by preventive health services or would be part of a routine checkup. Since varicella vaccination in those 12-years-old can be combined immunity, and errors in determining susceptibility at age 12 years). Other medical events related to these infections can be partly prevented as well: 29% of hospitalizations, 20% of deaths, and 38% of the loss in life expectancy when only 15-month-old children are vaccinated. If susceptible 12-year-olds are also immunized, the target group for vaccination would increase by < 100,000 persons. The number of avoided hospitalizations and deaths, however, would almost double (table  2) , since the adolescent strategy targets primarily the more severe varicella infections while neglecting (the generally mild) infections occurring before age 12 years. Expected costs and cost-effectiveness analysis. As shown in figure 1, the avoided (or incremental) direct costs are generally much lower than the avoided indirect costs under each strategy. The total net savings of the children strategy would be DM 161.3 million per cohort of 15-month-olds. If only direct medical costs were included, savings would no longer occur, but vaccination would still be attractive at a net medical care cost of DM 7.9 million, with relatively low CERs (DM 20.6/infection prevented or DM 19,735/life-year saved; table 3). The adolescent strategy would result in total net savings of DM 21.0 million per cohort of 12-year-olds, 18% of which (~DM 3.9 million) would be direct cost savings. Of the strategies analyzed, only the adolescent strategy resulted in direct cost savings, because proportionally more savings can be realized by preventing treatment costs for more severe varicella cases, which occur more frequently in older persons. The children including catch-up strategy would yield total net savings of DM 182.3 million per combined cohort of 15-month-old children and susceptible 12-year-olds but would add DM 4.0 million to the costs of medical care (CER, DM 9.6/infection prevented or DM 6915/life-year saved).
Cost-benefit analysis. If the natural units in which effects have been expressed can be valued in monetary terms, a costbenefit analysis can be done [21] . Table 4 shows benefit-tocost ratios (BCRs) for all three prevention strategies and illusExpected costs and numbers of effects were simulated for both prevention strategies for annual birth cohorts of 800,000 German neonates and compared with costs and effects occurring in the absence of prevention.
Expected effects. With the children vaccination strategy, 57% (384,620 infections) of all potential varicella infections after age 15 months can be prevented, whereas with the adolescent strategy only 37% of all potential infections after age 12 years can be prevented (table 2) . These percentages are rather low, due to the conservative assumptions adopted in the baseline (70% coverage rate, 90% protection rate, 15% waning with vaccination against rubella (or booster MMR), 50% of the administration costs was attributed to varicella vaccination at that age. Therefore, total vaccination costs were estimated as DM 80 (75 + 5) for both age groups.
In the absence of any prevention, an average of 89% of adolescents will acquire natural immunity to varicella by age 12 years (table 1) . For the adolescents and children including catch-up strategy, only 12-year-olds with no history of varicella require vaccination. On the basis of several studies, the sensitivity and specificity of determining a person's varicella history at age 12 years is estimated to be 97% and 70%, respectively [7, 18] .
Indirect costs. Indirect costs, which are due to productivity losses, must be taken into account to determine the full economic consequences of varicella on society. On the basis of Dutch and Belgian studies of indirect costs associated with productivity losses, we estimated an average cost of DM 200 per lost workday for complicated and uncomplicated varicella cases [19, 20] . The impact of varying this parameter will be tested in the sensitivity analysis. Lieu et al. [4] estimated a work loss cost of $201 per patient (1990 price level), whereas Ruse et al. [5] used $103 per day lost from work (1991 price level) for an average of 3.7 days. German parents stay home a mean of 2.6 days to care for a child with varicella infection [15] . For the small proportion of adults who contract the disease, a conservative estimate of 10 illness days was used to calculate productivity loss.
Baseline Results
NOTE. Intervention strategies against varicella were compared with nonintervention: vaccination of all healthy children between ages of 12 and 18 months (children), vaccination of all healthy 12-year-olds with negative varicella history (adolescents), and both strategies combined (children including catch-up). NOTE. Intervention strategies against varicella were compared with nonintervention: vaccination of all healthy children between ages of 12 and 18 months (children), vaccination of all healthy l2-year-olds with negative varicella history (adolescents), and both strategies combined (children including catch-up).
trates that indirect benefits outweigh direct benefits, since their inclusion multiplies (direct) BCRs by factors of """5, 3, and 5, respectively, for the three strategies. Thus, from the health care payer's point of view, for every Deutsche mark (DM) spent, DM 0.82, 1.94, and 0.92 can be recovered by implementing the respective strategies, whereas from society's viewpoint, the return on investment is, respectively, DM 4.60, 6.02, and 4.72 for every DM spent.
The conclusions from these baseline figures all point in the same direction: The adolescent strategy is the most efficient, because it focuses first on preventing more severe varicella cases. However, the nominal number of preventions is of a much smaller scale than with the other strategies, since the target group is also much smaller. This discrepancy is shown clearly by comparing the BCRs, which are relative measures, to the differences between benefits and costs, which are nominal measures (table 4) [22, 23] . According to the former measure, the adolescent strategy is preferred, but according to the latter, which includes avoided indirect costs, the adolescent strategy is the least preferable of the three. Since decision makers are primarily interested in direct medical cost savings and relative efficiency, the adolescent strategy would be chosen from this perspective. However, the adolescent strategy may be less acceptable from medical and practical points of view. According to the baseline results, the second best strategy would then be to include a catch-up provision in the children strategy during the first 11 years. During the first I 1 years of intervention, the discounted net direct costs would be DM 68.9 million without and DM 34.7 million with catching-up. With the inclusion of savings in indirect costs, the overall net savings would total .....,DM 1407 and 1590 million, respectively, implying that adding catch-up vaccination would save an additional DM 183 million in total costs (direct costs, DM 34.2 million) during the first 11 years.
Sensitivity and threshold analysis. Because of the uncertainty with regard to several crucial input parameters, it is CER for prevention strategies NOTE. Intervention strategies against varicella were compared with nonintervention: vaccination of all healthy children between ages of 12 and 18 months (children), vaccination of all healthy 12-year-olds with negative varicella history (adolescents), and both strategies combined (children including catch-up).
important to check the robustness of the findings by varying the input values within reasonable bounds. Table 5 shows results of a one-way sensitivity analysis. All net costs are per cohort. The costs for the children including catch-up strategy were not added to this table, since they are (if analyzed per cohort) the sum of the costs of the children and the adolescent strategies.
The total net savings were almost linearly related to changes in the costs of work loss: a reduction of 50% of the costs per day lost (",-;DM 100) leads to a reduction of .....,52% and 41% in total net savings for the children and the adolescent strategies, respectively. The threshold costs per workday lost, where total net savings become total net costs, were calculated as DM 9.35 and 4.27, respectively, for the children and the children including catch-up strategies. Thus, if a working person's productive contribution to society is valued at DM 10 per workday (which is very low by Western standards), total net savings can be realized by implementing either prevention strategy.
Other parameters with a large impact on total net savings for the target groups include vaccine efficacy and coverage. Adolescent vaccination is most sensitive to changes in the accuracy of the determination of varicella history, even more so than to changes in the costs of work loss. However, none of the large variations in the model parameters was sufficient to make either prevention strategy no longer cost-saving in total net costs (total net costs remained negative, indicating that savings would occur; NOTE. Intervention strategies against varicella were compared with nonintervention: vaccination of all healthy children between ages of 12 and 18 months (children), vaccination of all healthy 12-year-olds with negative varicella history (adolescent). DM, Deutsche mark.
nation strategy, where a 33% decrease in vaccine price leads to an increase of avoided net costs of medical care of~200%. Vaccine price changes have a greater bearing on the children strategy than on the adolescent strategy, since only~11% of l2-year-olds will need a vaccine dose. Vaccination of children is cost-effective from the health care payer's perspective at a cost of ::::::::DM 65.87 or if the baseline administration cost of DM 5 is maintained at a vaccine price of ::::::::DM 60.87. These threshold prices would be DM 150.23 and 68.50, respectively, for adolescent and children including catch-up vaccination.
Treatment costs also strongly affect the net costs of medical care in both the children and adolescent strategies. By changing the prescription frequency of acyclovir, the differences between the last two strategies become more apparent. Banning acyclovir altogether has a larger impact on the adolescent strategy than halving each treatment cost component, because the former would render adolescent vaccination no longer costsaving from a medical care payer's point of view (CER, DM 69/infection prevented or DM 11,620/life-year saved). This is due to treatment differences in relation to the patient's age. The adolescent strategy is no longer cost-saving when the uptake of acyclovir in varicella patients ?: l4-years-old is less thañ
40%.
Another factor to which net medical care costs are sensitive for adolescent vaccination is the accuracy of determining a child's varicella history at age 12 years. A decrease in the sensitivity (baseline, 97%) of this determination is bound to have a substantial negative influence on avoided medical care costs. Attributing a cost of DM 5 to this determination would reduce the net medical care savings by~92%.
Changes in the discount rate seem to have little influence on the outcome of the calculations, probably because most varicella infections occur at a young age and because there is no notable chronicity involved with varicella. The rate of waning immunity has a small effect because its consequences are far in the future and are therefore made less important, even when assuming, as we did, that a breakthrough case is treated similarly to a varicella case after natural infection.
We made a preliminary calculation with the assumption that a booster dose would be required 10 years after the initial vaccine dose. The influence of this extra booster on the direct costs is more important for the children than for the adolescent strategy. Net direct savings would still occur with the adolescent strategy, but the direct medical costs of the children strategy would increase by a factor of 5.
Discussion and Conclusion
Our economic evaluation of the introduction of routine childhood varicella immunization in Germany leads us to conclude that (from a societal perspective), the optimal feasible varicella prevention strategy is to start vaccinating I5-month-old children, to use catch-up vaccination of I2-year-olds for 11 years, and from the 12th year onward to continue routinely immunizing 15-month-old children.
If these strategies are adopted and assuming that 70% vaccine coverage can be attained, total net savings (including indirect costs) of OM 1.6 billion will be realized during the first 11 years, with net medical care costs of OM 34.7 million during the period. From year 12 onward, total net savings would be DM 161.3 million (net medical care costs, OM 7.9 million). From the viewpoint of society at large, every OM spent would yield a return of DM 4.72 during the first 11 years of intervention and OM 4.60 thereafter. In return for every OM invested in medical care, the health care payer would receive DM 0.92 during the first 11 years and OM 0.82 thereafter. Net savings in medical care could be realized for any strategy if the price of a vaccine dose is <OM 61.
These conclusions are not unconditional and are valid only if routine childhood varicella vaccination is mandated, if the varicella vaccine is integrated into the current MMR vaccination policy, and if government pays for vaccinations. Otherwise, a 70% coverage rate will not be attained, and the costs of administering the vaccine might not be as low as estimated. This is of vital importance, since low coverage will not only produce baleful consequences for the economic results but could also lead to a shift of infections to older age groups, creating a large pool of older susceptible persons who are at risk of more severe varicella.
If the above-mentioned conditions are met, we believe our economic conclusions are valid and that as with previous mass vaccination campaigns with MMR, there would be no danger for an infection shift to older age groups. In fact, in the absence of vaccination, such a shift has already been noted in certain tropical countries and in England and Wales, which could be another argument for organized vaccination [24, 25] . To exclude all doubts about the possibility of an age shift after vaccination, consideration could be given to routinely administering a varicella booster dose at age 12 years [26] . Currently, there are too many missing data concerning additional protection offered by a booster dose to make a relevant analysis of such a scenario. Thus, this question needs investigation in future analyses.
Since this study evaluated only the costs and benefits of varicella vaccination in Germany, where treatment costs for varicella are relatively high, its conclusions should not be extrapolated to other countries indiscriminately. However, results of a scenario better suited for other European countries, in which treatment costs were halved, did not seem to significantly alter our general conclusions.
Our results are comparable to those of Lieu et al. [4] , who reported cost-benefit ratios for varicella vaccination of US children of 0.90:1 and 5.40:1, respectively, without and with inclusion of indirect costs. Our corresponding ratios were 0.82: 1 and 4.60: 1. The CERs of Lieu et al. of $2.10 per infection prevented and $2500 per life-year saved compare well with our respective ratios of OM 20.6 and 19,735 DM (1990 dollars vs. 1995 OM), although Lieu et al. applied a gradually increasing coverage rate up to 97% in their analysis in children 6-years-old, whereas we used an immediate coverage rate of 70% at age 15 months. Furthermore, the treatment costs in our model were higher than those of Lieu et al. Due to their increasing coverage rate to age 6 years, their catch-up program was more cost-effective when a lower coverage rate in school-age childrenwas used; with a coverage of 70%, their catch-up program could be realized at an incremental cost of $7.30 per case prevented. From the medical care payer's point of view, Lieu et al. found a threshold baseline vaccine price of $31 versus our OM 61 (~$35). Total net savings in the models of Lieu et al. and Huse et al. [5] were $384 million per year (birth cohort, 4 million;~$99 per vaccinee) and $6.6 million ($66.47/ vaccinee). In our study, savings were~$92 million ($164/ vaccinee). All three studies illustrate that substantial total net savings can be realized.
In summary, it appears that routine childhood immunization against varicella in Germany can prevent much disease, and, under certain conditions, an immunization program could free up resources that may usefully be deployed elsewhere in the health care sector.
